Home > Research > Publications & Outputs > The trypanosome alternative oxidase

Research

Links

Text available via DOI:

Keywords

View graph of relations

The trypanosome alternative oxidase: A potential drug target?

Research output: Contribution to Journal/Magazine › Review article › peer-review

Published

Standard

The trypanosome alternative oxidase: A potential drug target? / Menzies, Stefanie K.; Tulloch, Lindsay B.; Florence, Gordon J. et al.
In: Parasitology, Vol. 145, No. 2, 01.02.2018, p. 175-183.

Research output: Contribution to Journal/Magazine › Review article › peer-review

Harvard

Menzies, SK, Tulloch, LB, Florence, GJ & Smith, TK 2018, 'The trypanosome alternative oxidase: A potential drug target?', Parasitology, vol. 145, no. 2, pp. 175-183. https://doi.org/10.1017/S0031182016002109

APA

Menzies, S. K., Tulloch, L. B., Florence, G. J., & Smith, T. K. (2018). The trypanosome alternative oxidase: A potential drug target? Parasitology, 145(2), 175-183. https://doi.org/10.1017/S0031182016002109

Vancouver

Menzies SK, Tulloch LB, Florence GJ, Smith TK. The trypanosome alternative oxidase: A potential drug target? Parasitology. 2018 Feb 1;145(2):175-183. Epub 2016 Nov 29. doi: 10.1017/S0031182016002109

Author

Menzies, Stefanie K. ; Tulloch, Lindsay B. ; Florence, Gordon J. et al. / The trypanosome alternative oxidase : A potential drug target?. In: Parasitology. 2018 ; Vol. 145, No. 2. pp. 175-183.

Bibtex

@article{8e76585294024e098f166e4d17d33699,
title = "The trypanosome alternative oxidase: A potential drug target?",
abstract = "New drugs against Trypanosoma brucei, the causative agent of Human African Trypanosomiasis, are urgently needed to replace the highly toxic and largely ineffective therapies currently used. The trypanosome alternative oxidase (TAO) is an essential and unique mitochondrial protein in these parasites and is absent from mammalian mitochondria, making it an attractive drug target. The structure and function of the protein are now well characterized, with several inhibitors reported in the literature, which show potential as clinical drug candidates. In this review, we provide an update on the functional activity and structural aspects of TAO. We then discuss TAO inhibitors reported to date, problems encountered with in vivo testing of these compounds, and discuss the future of TAO as a therapeutic target.",
keywords = "chemotherapy, drug discovery, human African trypanosomiasis, sleeping sickness, Trypanosoma brucei, Trypanosome alternative oxidase",
author = "Menzies, {Stefanie K.} and Tulloch, {Lindsay B.} and Florence, {Gordon J.} and Smith, {Terry K.}",
note = "Publisher Copyright: Copyright {\textcopyright} Cambridge University Press 2016.",
year = "2018",
month = feb,
day = "1",
doi = "10.1017/S0031182016002109",
language = "English",
volume = "145",
pages = "175--183",
journal = "Parasitology",
issn = "0031-1820",
publisher = "Cambridge University Press",
number = "2",

}

RIS

TY - JOUR

T1 - The trypanosome alternative oxidase

T2 - A potential drug target?

AU - Menzies, Stefanie K.

AU - Tulloch, Lindsay B.

AU - Florence, Gordon J.

AU - Smith, Terry K.

N1 - Publisher Copyright: Copyright © Cambridge University Press 2016.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - New drugs against Trypanosoma brucei, the causative agent of Human African Trypanosomiasis, are urgently needed to replace the highly toxic and largely ineffective therapies currently used. The trypanosome alternative oxidase (TAO) is an essential and unique mitochondrial protein in these parasites and is absent from mammalian mitochondria, making it an attractive drug target. The structure and function of the protein are now well characterized, with several inhibitors reported in the literature, which show potential as clinical drug candidates. In this review, we provide an update on the functional activity and structural aspects of TAO. We then discuss TAO inhibitors reported to date, problems encountered with in vivo testing of these compounds, and discuss the future of TAO as a therapeutic target.

AB - New drugs against Trypanosoma brucei, the causative agent of Human African Trypanosomiasis, are urgently needed to replace the highly toxic and largely ineffective therapies currently used. The trypanosome alternative oxidase (TAO) is an essential and unique mitochondrial protein in these parasites and is absent from mammalian mitochondria, making it an attractive drug target. The structure and function of the protein are now well characterized, with several inhibitors reported in the literature, which show potential as clinical drug candidates. In this review, we provide an update on the functional activity and structural aspects of TAO. We then discuss TAO inhibitors reported to date, problems encountered with in vivo testing of these compounds, and discuss the future of TAO as a therapeutic target.

KW - chemotherapy

KW - drug discovery

KW - human African trypanosomiasis

KW - sleeping sickness

KW - Trypanosoma brucei

KW - Trypanosome alternative oxidase

U2 - 10.1017/S0031182016002109

DO - 10.1017/S0031182016002109

M3 - Review article

C2 - 27894362

AN - SCOPUS:84997638231

VL - 145

SP - 175

EP - 183

JO - Parasitology

JF - Parasitology

SN - 0031-1820

IS - 2

ER -